PT1244805E - Complexos de distribuicao de proteina-lipido cationico-acido nucleico do nucleo viral - Google Patents

Complexos de distribuicao de proteina-lipido cationico-acido nucleico do nucleo viral

Info

Publication number
PT1244805E
PT1244805E PT00981481T PT00981481T PT1244805E PT 1244805 E PT1244805 E PT 1244805E PT 00981481 T PT00981481 T PT 00981481T PT 00981481 T PT00981481 T PT 00981481T PT 1244805 E PT1244805 E PT 1244805E
Authority
PT
Portugal
Prior art keywords
nucleic acid
noi
lipid
cationic protein
complex
Prior art date
Application number
PT00981481T
Other languages
English (en)
Inventor
Tagawa Toshiaki
A D Miller
E Perouzel
Murray Karl
Manvell Michelle
Alton Eric
Matthews David
Russell Willie
Original Assignee
Mitsubishi Chem Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Chem Corp filed Critical Mitsubishi Chem Corp
Publication of PT1244805E publication Critical patent/PT1244805E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
PT00981481T 1999-12-23 2000-12-12 Complexos de distribuicao de proteina-lipido cationico-acido nucleico do nucleo viral PT1244805E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9930533.6A GB9930533D0 (en) 1999-12-23 1999-12-23 Nucleic acid delivery

Publications (1)

Publication Number Publication Date
PT1244805E true PT1244805E (pt) 2006-07-31

Family

ID=10866964

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00981481T PT1244805E (pt) 1999-12-23 2000-12-12 Complexos de distribuicao de proteina-lipido cationico-acido nucleico do nucleo viral

Country Status (16)

Country Link
US (2) US20030153081A1 (pt)
EP (2) EP1244805B1 (pt)
JP (1) JP2003518388A (pt)
CN (1) CN100354426C (pt)
AT (1) ATE318322T1 (pt)
AU (1) AU781356B2 (pt)
CA (1) CA2395454A1 (pt)
CZ (1) CZ298353B6 (pt)
DE (1) DE60026164T2 (pt)
DK (1) DK1244805T3 (pt)
ES (1) ES2258986T3 (pt)
GB (1) GB9930533D0 (pt)
PT (1) PT1244805E (pt)
RU (1) RU2267536C2 (pt)
UA (1) UA77393C2 (pt)
WO (1) WO2001048233A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0118517D0 (en) * 2001-07-30 2001-09-19 Mitsubishi Tokyo Pharm Inc Compound
FR2829136B1 (fr) * 2001-08-29 2006-11-17 Aventis Pharma Sa Derives lipidiques d'aminoglycosides
WO2003018603A1 (fr) * 2001-08-29 2003-03-06 Aventis Pharma S.A. Derives lipidiques d'aminoglycosides_pour la transfection
BRPI0411505A (pt) 2003-06-18 2006-07-25 Yissum Res Dev Co uso de um composto, método para modular a resposta imune de um indivìduo, composição farmacêutica, vacina, complexo, e, kit para a captura de uma molécula biologicamente ativa
US7906122B2 (en) 2003-06-18 2011-03-15 Yissum Research Development Company Of The Hebrew University Of Jersusalem Sphingoid polyalkylamine conjugates for Hepatitis B virus vaccination
GB0418172D0 (en) * 2004-08-13 2004-09-15 Ic Vec Ltd Vector
US20090155853A1 (en) * 2005-11-18 2009-06-18 Gary Nabel Non-viral gene delivery complex
US20110002851A1 (en) * 2006-11-03 2011-01-06 Medigene Ag Cationic Colloidal Carriers for Delivery of Active Agents to the Blood-Brain Barrier in the Course of Neuroinflammatory Diseases
WO2008056623A1 (fr) * 2006-11-09 2008-05-15 Daiichi Sankyo Company, Limited Composition pour l'introduction d'acide nucléique
EP2105145A1 (en) 2008-03-27 2009-09-30 ETH Zürich Method for muscle-specific delivery lipid-conjugated oligonucleotides
WO2010042751A2 (en) * 2008-10-08 2010-04-15 Chimeros Inc. Chimeric therapeutics, compositions, and methods for using same
JP5747282B2 (ja) * 2008-11-10 2015-07-15 テクミラ ファーマシューティカルズ コーポレイションTekmira Pharmaceuticals Corporation 治療薬を送達するための新規な脂質及び組成物
WO2010120874A2 (en) * 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
WO2013036973A2 (en) 2011-09-09 2013-03-14 Biomed Realty, L.P. Methods and compositions for controlling assembly of viral proteins
CA3165769A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
EP3160938B1 (en) 2014-06-25 2020-09-16 Acuitas Therapeutics Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3313829B1 (en) 2015-06-29 2024-04-10 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
JP2018532404A (ja) * 2015-10-14 2018-11-08 ライフ テクノロジーズ コーポレーション リボ核タンパク質トランスフェクション薬剤
HRP20230209T1 (hr) 2015-10-28 2023-04-14 Acuitas Therapeutics Inc. Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
MX2018013919A (es) 2016-06-09 2019-04-15 Curevac Ag Portadores hibridos para cargas de acido nucleico.
WO2017212006A1 (en) * 2016-06-09 2017-12-14 Curevac Ag Hybrid carriers for nucleic acid cargo
US11357856B2 (en) 2017-04-13 2022-06-14 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
AU2018256867A1 (en) 2017-04-27 2019-11-14 The Johns Hopkins University Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C virus
CA3061612A1 (en) 2017-04-28 2018-11-01 Acuitas Therapeutics, Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
JP7355731B2 (ja) 2017-08-16 2023-10-03 アクイタス セラピューティクス インコーポレイテッド 脂質ナノ粒子製剤における使用のための脂質
WO2019036030A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
US11542225B2 (en) 2017-08-17 2023-01-03 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US11453639B2 (en) 2019-01-11 2022-09-27 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
JP2021016370A (ja) * 2019-07-23 2021-02-15 株式会社東芝 核酸導入キャリア、核酸導入キャリアセット、核酸導入組成物及び核酸導入方法
CN110408656A (zh) * 2019-07-29 2019-11-05 成都朴名生物科技有限公司 脂多聚物体及其制备方法、采用脂多聚物体将基因编辑质粒导入真核细胞的方法
CN110452303B (zh) * 2019-08-08 2022-03-04 中国科学院武汉病毒研究所 共价连接核酸和肽或蛋白的方法及应用
CN111394313A (zh) * 2020-04-01 2020-07-10 河南科技学院 一种人造细胞及其制备方法
EP4182297A1 (en) 2020-07-16 2023-05-24 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
CN114656422B (zh) * 2022-04-22 2023-05-23 重庆理工大学 一种新型氮杂冠醚化合物及其阳离子脂质体、制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH574396A5 (pt) * 1969-12-29 1976-04-15 Richter Gedeon Vegyeszet
US4189431A (en) * 1975-08-04 1980-02-19 The Board of Trustees of Leland Stanford Junior University Alkinyl terminating groups in biogenetic-like cyclizations to steroids
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
IL112372A (en) * 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
US5510510A (en) * 1994-05-10 1996-04-23 Bristol-Meyers Squibb Company Inhibitors of farnesyl protein transferase
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US5736392A (en) * 1995-06-07 1998-04-07 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
CN1181422A (zh) * 1996-10-31 1998-05-13 上海市肿瘤研究所 与生长因子受体结合的多肽所构建的基因转移载体
AU3285000A (en) * 1999-03-09 2000-09-28 Akzo Nobel N.V. 22r-hydroxycholesta-8,14-diene derivatives for the inhibition of meiosis

Also Published As

Publication number Publication date
DE60026164T2 (de) 2006-11-16
DK1244805T3 (da) 2006-06-26
EP1566445A2 (en) 2005-08-24
GB9930533D0 (en) 2000-02-16
ATE318322T1 (de) 2006-03-15
AU1871601A (en) 2001-07-09
CA2395454A1 (en) 2001-07-05
WO2001048233A1 (en) 2001-07-05
AU781356B2 (en) 2005-05-19
JP2003518388A (ja) 2003-06-10
EP1244805A1 (en) 2002-10-02
US20090209037A1 (en) 2009-08-20
EP1566445A3 (en) 2005-08-31
RU2267536C2 (ru) 2006-01-10
CZ20022193A3 (cs) 2003-02-12
CN1434870A (zh) 2003-08-06
CN100354426C (zh) 2007-12-12
RU2002119560A (ru) 2004-03-27
UA77393C2 (en) 2006-12-15
EP1244805B1 (en) 2006-02-22
US20030153081A1 (en) 2003-08-14
DE60026164D1 (de) 2006-04-27
ES2258986T3 (es) 2006-09-16
CZ298353B6 (cs) 2007-09-05

Similar Documents

Publication Publication Date Title
PT1244805E (pt) Complexos de distribuicao de proteina-lipido cationico-acido nucleico do nucleo viral
DE69834022D1 (de) Fusionproteine für intra- und interzelluläre transport und deren verwendungen
NZ320276A (en) Method and preparations for stabilizing biological materials by drying methods without freezing
NZ244291A (en) Virus-antibody conjugates for introducing nucleic acids into higher eukaryotic cells
AU9174398A (en) Peptides
WO2001075087A3 (en) Subtilisin variants
FI931109A0 (fi) Peptider och nukleinsyrasekvenser, som haenfoer sig till epstein-barr-virus
PT789766E (pt) Particulas quimericas do tipo papilomavirus
WO2002002783A3 (en) Expression vectors
WO2002006457A3 (en) Novel lipase genes
WO2000077233A3 (en) Complement-resistant non-mammalian dna viruses and uses thereof
WO1999067382A3 (en) Angiopoietin-like growth factor sequences
WO2005003315A3 (en) Compositions and methods for peptide-assisted transfection
WO1997031934A3 (de) Neue metabolisierbare lipopolyamine, deren darstellung und anwendung
CA2379346A1 (en) Conjugate for mediating cell-specific, compartment-specific or membrane-specific transport of active substances
CY1107431T1 (el) Σωματιδια για γoνιδιακη θεραπεια
WO2000075358A3 (en) Mammalian toll homologues and uses thereof
EP0805204A3 (de) Nebenhoden-spezifisches Rezeptorprotein und dessen Verwendung
EP1515738A4 (en) SCYTORIVINS AND CONJUGATES, FUSION PROTEINS, NUCLEIC ACIDS, VECTORS, HOST CELLS, COMPOSITIONS AND RELATED ANTIBODIES, AND METHODS OF USING SCYTOVIRINS
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
AU3282900A (en) Target cell-specific, multivalent proteins (mvp)
DE69535024D1 (de) Verpackungszellinie zur transkomplementierung von defektiven retroviren-vektoren
WO2000075352A3 (en) Hcv/bvdv chimeric genomes and uses thereof
WO2002004601A3 (en) Mammalian mdm2 binding proteins and uses thereof
GB2363607A (en) Method for selecting improved vectors